Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program
Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real‐life cohort of 16,703 cons...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 2019-12, Vol.145 (12), p.3359-3369 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3369 |
|---|---|
| container_issue | 12 |
| container_start_page | 3359 |
| container_title | International journal of cancer |
| container_volume | 145 |
| creator | Jacot, William Heudel, Pierre‐Etienne Fraisse, Julien Gourgou, Sophie Guiu, Séverine Dalenc, Florence Pistilli, Barbara Campone, Mario Levy, Christelle Debled, Marc Leheurteur, Marianne Chaix, Marie Lefeuvre, Claudia Goncalves, Anthony Uwer, Lionel Ferrero, Jean‐Marc Eymard, Jean‐Christophe Petit, Thierry Mouret‐Reynier, Marie‐Ange Courtinard, Coralie Cottu, Paul Robain, Mathieu Mailliez, Audrey |
| description | Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real‐life cohort of 16,703 consecutive MBC patients initiating their first metastatic therapeutic line between 2008 and 2014. Primary and secondary objectives were overall survival (OS) and progression‐free survival (PFS). An imbalance was seen for HER2+ tumors and concomitant anti‐HER2 targeted therapies use, we thus performed a subanalysis in HER2− patients. PFS and OS were significantly better in EM patients in third and fourth lines, compared to “Other chemotherapies” patients (PFS: 4.14 vs. 3.02 months, p = 0.0010; 3.61 vs. 2.53 months, p = 0.0102, third and fourth‐line; OS: 11.27 vs. 7.65 months, p = 0.0001; 10.91 vs. 5.95 months, p |
| doi_str_mv | 10.1002/ijc.32402 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02454479v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2232003077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4222-98dda76e0a8526a39d8de9e5c29f3a7938d919db8be2d0775dcbd60550f6bb353</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhiMEokvhwB9AlrjAIe3YjvNxrFZLW7QIiY-z5diT1isnWexk0d449shv5JcwZdsiIXGyZ97H74z1ZtlLDiccQJz6jT2RogDxKFtwaKocBFePswVpkFdclkfZs5Q2AJwrKJ5mR5JDXamyWGQ3n9CEXz9-Bt8hM3byOz_t2dgxjL6dgx9Yj2kfzERqPw5XVE4mTWbylrUR6cqsGSxGtqUeDlNi9Ga6RtbPgSDqkDaQNg4msLFNGHf31erzhxXbxvEqmv559qQzIeGLu_M4-_pu9WV5ka8_nl8uz9a5LYQQeVM7Z6oSwdRKlEY2rnbYoLKi6aSpGlm7hjeurVsUDqpKOdu6EpSCrmxbqeRx9vbge22C3kbfm7jXo_H64mytb3sgClUUVbPjxL45sLTjtxnTpHufLIZgBhznpIWQAkDSGEJf_4NuxjnSJ4kigKtSFvB3uI1jShG7hw046NsoNUWp_0RJ7Ks7x7nt0T2Q99kRcHoAvvuA-_876cv3y4Plb63wqck</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2307156340</pqid></control><display><type>article</type><title>Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Jacot, William ; Heudel, Pierre‐Etienne ; Fraisse, Julien ; Gourgou, Sophie ; Guiu, Séverine ; Dalenc, Florence ; Pistilli, Barbara ; Campone, Mario ; Levy, Christelle ; Debled, Marc ; Leheurteur, Marianne ; Chaix, Marie ; Lefeuvre, Claudia ; Goncalves, Anthony ; Uwer, Lionel ; Ferrero, Jean‐Marc ; Eymard, Jean‐Christophe ; Petit, Thierry ; Mouret‐Reynier, Marie‐Ange ; Courtinard, Coralie ; Cottu, Paul ; Robain, Mathieu ; Mailliez, Audrey</creator><creatorcontrib>Jacot, William ; Heudel, Pierre‐Etienne ; Fraisse, Julien ; Gourgou, Sophie ; Guiu, Séverine ; Dalenc, Florence ; Pistilli, Barbara ; Campone, Mario ; Levy, Christelle ; Debled, Marc ; Leheurteur, Marianne ; Chaix, Marie ; Lefeuvre, Claudia ; Goncalves, Anthony ; Uwer, Lionel ; Ferrero, Jean‐Marc ; Eymard, Jean‐Christophe ; Petit, Thierry ; Mouret‐Reynier, Marie‐Ange ; Courtinard, Coralie ; Cottu, Paul ; Robain, Mathieu ; Mailliez, Audrey</creatorcontrib><description>Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real‐life cohort of 16,703 consecutive MBC patients initiating their first metastatic therapeutic line between 2008 and 2014. Primary and secondary objectives were overall survival (OS) and progression‐free survival (PFS). An imbalance was seen for HER2+ tumors and concomitant anti‐HER2 targeted therapies use, we thus performed a subanalysis in HER2− patients. PFS and OS were significantly better in EM patients in third and fourth lines, compared to “Other chemotherapies” patients (PFS: 4.14 vs. 3.02 months, p = 0.0010; 3.61 vs. 2.53 months, p = 0.0102, third and fourth‐line; OS: 11.27 vs. 7.65 months, p = 0.0001; 10.91 vs. 5.95 months, p < 0.0001, third and fourth‐line). No significant difference was reported in second‐line (PFS: 5.06 vs. 4.14 months, p = 0.1171; OS: 13.99 vs. 11.66 months, p = 0.151). Among HER2− patients, a significant difference was seen for all lines, including 2nd‐line (PFS: 4.57 vs. 3.91 months, p = 0.0379; OS: 14.98 vs. 10.51 months, p = 0.0113). In this large real‐world database, HER2‐negative MBC patients receiving EM in second or later CT line presented significantly better PFS and OS. This difference disappeared in second line in the overall population, probably because of the imbalance in HER2‐targeted treatments use. Our results mirror those of the published randomized trials. The effect of anti‐HER2 therapies addition in this setting still needs to be defined.
What's new?
An emerging therapy for metastatic breast cancer may extend survival over other chemotherapies. Eribulin mesylate (EM), a microtubule‐dynamics inhibitor, was approved by the FDA in 2010 as a later‐line therapy for metastatic breast cancer. Here, the authors evaluated EM effectiveness by analyzing data from 16,703 MBC patients. Treatment with EM as a third or fourth line therapy improved survival compared to other chemotherapy, but as a second line therapy, EM only benefited patients with HER2‐ disease. Since this trial was retrospective, not randomized, different proportions of patients in the two treatment groups received HER‐targeting therapies, which may have influenced the result.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.32402</identifier><identifier>PMID: 31087564</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Aged ; Antineoplastic Agents - therapeutic use ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Cancer ; Chemotherapy ; Clinical trials ; Disease-Free Survival ; ErbB-2 protein ; eribulin ; Female ; Furans - therapeutic use ; Humans ; Ketones - therapeutic use ; Life Sciences ; Medical research ; Metastases ; Metastasis ; metastatic breast cancer ; Middle Aged ; Progression-Free Survival ; real‐life cohort ; Receptor, ErbB-2 - metabolism ; Retrospective Studies ; Survival ; Tumors</subject><ispartof>International journal of cancer, 2019-12, Vol.145 (12), p.3359-3369</ispartof><rights>2019 UICC</rights><rights>2019 UICC.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4222-98dda76e0a8526a39d8de9e5c29f3a7938d919db8be2d0775dcbd60550f6bb353</citedby><cites>FETCH-LOGICAL-c4222-98dda76e0a8526a39d8de9e5c29f3a7938d919db8be2d0775dcbd60550f6bb353</cites><orcidid>0000-0001-7834-061X ; 0000-0002-5196-5908 ; 0000-0003-0572-5222 ; 0000-0001-6434-3932 ; 0000-0001-7570-7439 ; 0000-0002-8746-0725</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.32402$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.32402$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31087564$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.umontpellier.fr/hal-02454479$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Jacot, William</creatorcontrib><creatorcontrib>Heudel, Pierre‐Etienne</creatorcontrib><creatorcontrib>Fraisse, Julien</creatorcontrib><creatorcontrib>Gourgou, Sophie</creatorcontrib><creatorcontrib>Guiu, Séverine</creatorcontrib><creatorcontrib>Dalenc, Florence</creatorcontrib><creatorcontrib>Pistilli, Barbara</creatorcontrib><creatorcontrib>Campone, Mario</creatorcontrib><creatorcontrib>Levy, Christelle</creatorcontrib><creatorcontrib>Debled, Marc</creatorcontrib><creatorcontrib>Leheurteur, Marianne</creatorcontrib><creatorcontrib>Chaix, Marie</creatorcontrib><creatorcontrib>Lefeuvre, Claudia</creatorcontrib><creatorcontrib>Goncalves, Anthony</creatorcontrib><creatorcontrib>Uwer, Lionel</creatorcontrib><creatorcontrib>Ferrero, Jean‐Marc</creatorcontrib><creatorcontrib>Eymard, Jean‐Christophe</creatorcontrib><creatorcontrib>Petit, Thierry</creatorcontrib><creatorcontrib>Mouret‐Reynier, Marie‐Ange</creatorcontrib><creatorcontrib>Courtinard, Coralie</creatorcontrib><creatorcontrib>Cottu, Paul</creatorcontrib><creatorcontrib>Robain, Mathieu</creatorcontrib><creatorcontrib>Mailliez, Audrey</creatorcontrib><title>Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real‐life cohort of 16,703 consecutive MBC patients initiating their first metastatic therapeutic line between 2008 and 2014. Primary and secondary objectives were overall survival (OS) and progression‐free survival (PFS). An imbalance was seen for HER2+ tumors and concomitant anti‐HER2 targeted therapies use, we thus performed a subanalysis in HER2− patients. PFS and OS were significantly better in EM patients in third and fourth lines, compared to “Other chemotherapies” patients (PFS: 4.14 vs. 3.02 months, p = 0.0010; 3.61 vs. 2.53 months, p = 0.0102, third and fourth‐line; OS: 11.27 vs. 7.65 months, p = 0.0001; 10.91 vs. 5.95 months, p < 0.0001, third and fourth‐line). No significant difference was reported in second‐line (PFS: 5.06 vs. 4.14 months, p = 0.1171; OS: 13.99 vs. 11.66 months, p = 0.151). Among HER2− patients, a significant difference was seen for all lines, including 2nd‐line (PFS: 4.57 vs. 3.91 months, p = 0.0379; OS: 14.98 vs. 10.51 months, p = 0.0113). In this large real‐world database, HER2‐negative MBC patients receiving EM in second or later CT line presented significantly better PFS and OS. This difference disappeared in second line in the overall population, probably because of the imbalance in HER2‐targeted treatments use. Our results mirror those of the published randomized trials. The effect of anti‐HER2 therapies addition in this setting still needs to be defined.
What's new?
An emerging therapy for metastatic breast cancer may extend survival over other chemotherapies. Eribulin mesylate (EM), a microtubule‐dynamics inhibitor, was approved by the FDA in 2010 as a later‐line therapy for metastatic breast cancer. Here, the authors evaluated EM effectiveness by analyzing data from 16,703 MBC patients. Treatment with EM as a third or fourth line therapy improved survival compared to other chemotherapy, but as a second line therapy, EM only benefited patients with HER2‐ disease. Since this trial was retrospective, not randomized, different proportions of patients in the two treatment groups received HER‐targeting therapies, which may have influenced the result.</description><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Disease-Free Survival</subject><subject>ErbB-2 protein</subject><subject>eribulin</subject><subject>Female</subject><subject>Furans - therapeutic use</subject><subject>Humans</subject><subject>Ketones - therapeutic use</subject><subject>Life Sciences</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>metastatic breast cancer</subject><subject>Middle Aged</subject><subject>Progression-Free Survival</subject><subject>real‐life cohort</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Retrospective Studies</subject><subject>Survival</subject><subject>Tumors</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1v1DAQhiMEokvhwB9AlrjAIe3YjvNxrFZLW7QIiY-z5diT1isnWexk0d449shv5JcwZdsiIXGyZ97H74z1ZtlLDiccQJz6jT2RogDxKFtwaKocBFePswVpkFdclkfZs5Q2AJwrKJ5mR5JDXamyWGQ3n9CEXz9-Bt8hM3byOz_t2dgxjL6dgx9Yj2kfzERqPw5XVE4mTWbylrUR6cqsGSxGtqUeDlNi9Ga6RtbPgSDqkDaQNg4msLFNGHf31erzhxXbxvEqmv559qQzIeGLu_M4-_pu9WV5ka8_nl8uz9a5LYQQeVM7Z6oSwdRKlEY2rnbYoLKi6aSpGlm7hjeurVsUDqpKOdu6EpSCrmxbqeRx9vbge22C3kbfm7jXo_H64mytb3sgClUUVbPjxL45sLTjtxnTpHufLIZgBhznpIWQAkDSGEJf_4NuxjnSJ4kigKtSFvB3uI1jShG7hw046NsoNUWp_0RJ7Ks7x7nt0T2Q99kRcHoAvvuA-_876cv3y4Plb63wqck</recordid><startdate>20191215</startdate><enddate>20191215</enddate><creator>Jacot, William</creator><creator>Heudel, Pierre‐Etienne</creator><creator>Fraisse, Julien</creator><creator>Gourgou, Sophie</creator><creator>Guiu, Séverine</creator><creator>Dalenc, Florence</creator><creator>Pistilli, Barbara</creator><creator>Campone, Mario</creator><creator>Levy, Christelle</creator><creator>Debled, Marc</creator><creator>Leheurteur, Marianne</creator><creator>Chaix, Marie</creator><creator>Lefeuvre, Claudia</creator><creator>Goncalves, Anthony</creator><creator>Uwer, Lionel</creator><creator>Ferrero, Jean‐Marc</creator><creator>Eymard, Jean‐Christophe</creator><creator>Petit, Thierry</creator><creator>Mouret‐Reynier, Marie‐Ange</creator><creator>Courtinard, Coralie</creator><creator>Cottu, Paul</creator><creator>Robain, Mathieu</creator><creator>Mailliez, Audrey</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-7834-061X</orcidid><orcidid>https://orcid.org/0000-0002-5196-5908</orcidid><orcidid>https://orcid.org/0000-0003-0572-5222</orcidid><orcidid>https://orcid.org/0000-0001-6434-3932</orcidid><orcidid>https://orcid.org/0000-0001-7570-7439</orcidid><orcidid>https://orcid.org/0000-0002-8746-0725</orcidid></search><sort><creationdate>20191215</creationdate><title>Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program</title><author>Jacot, William ; Heudel, Pierre‐Etienne ; Fraisse, Julien ; Gourgou, Sophie ; Guiu, Séverine ; Dalenc, Florence ; Pistilli, Barbara ; Campone, Mario ; Levy, Christelle ; Debled, Marc ; Leheurteur, Marianne ; Chaix, Marie ; Lefeuvre, Claudia ; Goncalves, Anthony ; Uwer, Lionel ; Ferrero, Jean‐Marc ; Eymard, Jean‐Christophe ; Petit, Thierry ; Mouret‐Reynier, Marie‐Ange ; Courtinard, Coralie ; Cottu, Paul ; Robain, Mathieu ; Mailliez, Audrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4222-98dda76e0a8526a39d8de9e5c29f3a7938d919db8be2d0775dcbd60550f6bb353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Disease-Free Survival</topic><topic>ErbB-2 protein</topic><topic>eribulin</topic><topic>Female</topic><topic>Furans - therapeutic use</topic><topic>Humans</topic><topic>Ketones - therapeutic use</topic><topic>Life Sciences</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>metastatic breast cancer</topic><topic>Middle Aged</topic><topic>Progression-Free Survival</topic><topic>real‐life cohort</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Retrospective Studies</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jacot, William</creatorcontrib><creatorcontrib>Heudel, Pierre‐Etienne</creatorcontrib><creatorcontrib>Fraisse, Julien</creatorcontrib><creatorcontrib>Gourgou, Sophie</creatorcontrib><creatorcontrib>Guiu, Séverine</creatorcontrib><creatorcontrib>Dalenc, Florence</creatorcontrib><creatorcontrib>Pistilli, Barbara</creatorcontrib><creatorcontrib>Campone, Mario</creatorcontrib><creatorcontrib>Levy, Christelle</creatorcontrib><creatorcontrib>Debled, Marc</creatorcontrib><creatorcontrib>Leheurteur, Marianne</creatorcontrib><creatorcontrib>Chaix, Marie</creatorcontrib><creatorcontrib>Lefeuvre, Claudia</creatorcontrib><creatorcontrib>Goncalves, Anthony</creatorcontrib><creatorcontrib>Uwer, Lionel</creatorcontrib><creatorcontrib>Ferrero, Jean‐Marc</creatorcontrib><creatorcontrib>Eymard, Jean‐Christophe</creatorcontrib><creatorcontrib>Petit, Thierry</creatorcontrib><creatorcontrib>Mouret‐Reynier, Marie‐Ange</creatorcontrib><creatorcontrib>Courtinard, Coralie</creatorcontrib><creatorcontrib>Cottu, Paul</creatorcontrib><creatorcontrib>Robain, Mathieu</creatorcontrib><creatorcontrib>Mailliez, Audrey</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jacot, William</au><au>Heudel, Pierre‐Etienne</au><au>Fraisse, Julien</au><au>Gourgou, Sophie</au><au>Guiu, Séverine</au><au>Dalenc, Florence</au><au>Pistilli, Barbara</au><au>Campone, Mario</au><au>Levy, Christelle</au><au>Debled, Marc</au><au>Leheurteur, Marianne</au><au>Chaix, Marie</au><au>Lefeuvre, Claudia</au><au>Goncalves, Anthony</au><au>Uwer, Lionel</au><au>Ferrero, Jean‐Marc</au><au>Eymard, Jean‐Christophe</au><au>Petit, Thierry</au><au>Mouret‐Reynier, Marie‐Ange</au><au>Courtinard, Coralie</au><au>Cottu, Paul</au><au>Robain, Mathieu</au><au>Mailliez, Audrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2019-12-15</date><risdate>2019</risdate><volume>145</volume><issue>12</issue><spage>3359</spage><epage>3369</epage><pages>3359-3369</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><abstract>Eribulin mesylate (EM) was recently approved for metastatic breast cancer (MBC) chemotherapy (CT) in late lines by the FDA, with debated results in second line. We evaluated outcomes in breast cancer patients receiving EM as second, third and fourth line in a national real‐life cohort of 16,703 consecutive MBC patients initiating their first metastatic therapeutic line between 2008 and 2014. Primary and secondary objectives were overall survival (OS) and progression‐free survival (PFS). An imbalance was seen for HER2+ tumors and concomitant anti‐HER2 targeted therapies use, we thus performed a subanalysis in HER2− patients. PFS and OS were significantly better in EM patients in third and fourth lines, compared to “Other chemotherapies” patients (PFS: 4.14 vs. 3.02 months, p = 0.0010; 3.61 vs. 2.53 months, p = 0.0102, third and fourth‐line; OS: 11.27 vs. 7.65 months, p = 0.0001; 10.91 vs. 5.95 months, p < 0.0001, third and fourth‐line). No significant difference was reported in second‐line (PFS: 5.06 vs. 4.14 months, p = 0.1171; OS: 13.99 vs. 11.66 months, p = 0.151). Among HER2− patients, a significant difference was seen for all lines, including 2nd‐line (PFS: 4.57 vs. 3.91 months, p = 0.0379; OS: 14.98 vs. 10.51 months, p = 0.0113). In this large real‐world database, HER2‐negative MBC patients receiving EM in second or later CT line presented significantly better PFS and OS. This difference disappeared in second line in the overall population, probably because of the imbalance in HER2‐targeted treatments use. Our results mirror those of the published randomized trials. The effect of anti‐HER2 therapies addition in this setting still needs to be defined.
What's new?
An emerging therapy for metastatic breast cancer may extend survival over other chemotherapies. Eribulin mesylate (EM), a microtubule‐dynamics inhibitor, was approved by the FDA in 2010 as a later‐line therapy for metastatic breast cancer. Here, the authors evaluated EM effectiveness by analyzing data from 16,703 MBC patients. Treatment with EM as a third or fourth line therapy improved survival compared to other chemotherapy, but as a second line therapy, EM only benefited patients with HER2‐ disease. Since this trial was retrospective, not randomized, different proportions of patients in the two treatment groups received HER‐targeting therapies, which may have influenced the result.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>31087564</pmid><doi>10.1002/ijc.32402</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7834-061X</orcidid><orcidid>https://orcid.org/0000-0002-5196-5908</orcidid><orcidid>https://orcid.org/0000-0003-0572-5222</orcidid><orcidid>https://orcid.org/0000-0001-6434-3932</orcidid><orcidid>https://orcid.org/0000-0001-7570-7439</orcidid><orcidid>https://orcid.org/0000-0002-8746-0725</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2019-12, Vol.145 (12), p.3359-3369 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02454479v1 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Aged Antineoplastic Agents - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer Chemotherapy Clinical trials Disease-Free Survival ErbB-2 protein eribulin Female Furans - therapeutic use Humans Ketones - therapeutic use Life Sciences Medical research Metastases Metastasis metastatic breast cancer Middle Aged Progression-Free Survival real‐life cohort Receptor, ErbB-2 - metabolism Retrospective Studies Survival Tumors |
| title | Real‐life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A10%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%E2%80%90life%20activity%20of%20eribulin%20mesylate%20among%20metastatic%20breast%20cancer%20patients%20in%20the%20multicenter%20national%20observational%20ESME%20program&rft.jtitle=International%20journal%20of%20cancer&rft.au=Jacot,%20William&rft.date=2019-12-15&rft.volume=145&rft.issue=12&rft.spage=3359&rft.epage=3369&rft.pages=3359-3369&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.32402&rft_dat=%3Cproquest_hal_p%3E2232003077%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2307156340&rft_id=info:pmid/31087564&rfr_iscdi=true |